Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Brensocatib reduced bronchiectasis exacerbations

Key clinical point: Brensocatib may be an effective nonantibiotic agent for treating inflammation in bronchiectasis.

Major finding: Both the 10-mg and 25-mg doses of brensocatib reduced exacerbations, compared with placebo.

Study details: Randomized placebo-controlled trial comparing two brensocatib doses in 256 adults with bronchiectasis.

Disclosures: Dr. Chalmers disclosed consultancy with and research funding from Insmed, which funded the study. Dr. Taylor-Cousar has disclosed grants and/or personal fees from various companies.